Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery by Cheng-Che Tu et al.
RESEARCH ARTICLE Open Access
Prognostic histological factors in patients
with esophageal squamous cell carcinoma
after preoperative chemoradiation followed
by surgery
Cheng-Che Tu1,2,3, Po-Kuei Hsu1,2,5*, Ling-I Chien4, Wan-Chen Liu4, Chien-Sheng Huang1,2, Chih-Cheng Hsieh1,2,
Han-Shui Hsu1,2 and Yu-Chung Wu1,2
Abstract
Background: Pathological response is an important marker for tumor aggressiveness in patients with esophageal
squamous cell carcinoma (ESCC) who receive preoperative chemoradiation followed by esophagectomy. We aim to
evaluate the prognostic value of histological factors after trimodality treatments.
Methods: 91 patients who received preoperative chemoradiation followed by transthoracic esophagectomy
between 2009 and 2014 were included. The pathological examination was reviewed. Overall survival and disease
free survival were recorded. Survival analysis was performed using the Cox regression model, and the survival
curves were compared by the log-rank test.
Results: Survival analysis showed lymphovascular invasion (LVI, hazard ratio [HR]: 2.009, p = 0.029), perineural
invasion (PNI, HR: 2.226, p = 0.019), ypN stage (HR: 2.041, p = 0.019), extracapsular invasion (ECI, HR: 2.804, p = 0.003),
and incomplete resection (HR: 1.897, p = 0.039) as unfavorable prognostic factors affecting overall survival (OS).
Moreover, tumor regression grade (TRG, HR: 1.834, p = 0.038), LVI (HR: 1.975, p = 0.038), ECI (HR: 2.836, p = 0.003), and
incomplete resection (HR: 2.254, p = 0.007) adversely affected disease-free survival (DFS). Prognostic classification
based on poor primary tumor (TRG2/3, LVI(+), and PNI (+)), lymph node (ypN(+) and ECI(+)), and surgical
(incomplete resection) factors significantly predicts OS (p = 0.013) and DFS (p = 0.017). However, the use of
postoperative adjuvant therapy was not a significant prognostic factor even in medium- and high-risk ESCC
patients who underwent trimodality treatments.
Conclusions: Histological factors, including primary tumor, lymph node, and surgical factors has high prognostic
value for predicting outcomes in ESCC patients receiving preoperative chemoradiation followed by surgery.
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Background
Trimodality treatments, which includes preoperative che-
moradiation and surgery, is the approach recommended
by the National Comprehensive Cancer Network (NCCN)
clinical practice guidelines for most locally advanced
esophageal cancers [1]. In the prospective randomized
CROSS (Chemoradiotherapy for Oesophageal Cancer
Followed by Surgery Study) study, the median overall
survival (OS) was 49.4 months in the preoperative
chemoradiation plus surgery group vs. 24.0 months in
the surgery alone group [2]. However, considerable
prognostic differences resulting from varied response
to chemoradiation have been observed in patients re-
ceiving trimodality treatment. Patients with a partial
response to preoperative chemoradiation or no re-
sponse at all were more likely to have disease recur-
rence than those with a complete response [3].
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Moreover, pathologic non-responders to chemoradia-
tion had no survival benefit when compared with pa-
tients who underwent only surgery [4–6]. To evaluate
the prognostic impact of pathologic response and pro-
vide prognostic discrimination in esophageal cancer
patients who received preoperative chemoradiation
followed by surgery, a combined classification of pri-
mary tumor regression and lymph node status has
been recently proposed by Holscher et al. [7] Al-
though patients with a major response (defined by
the presence of less than 10% of vital cells in the pri-
mary tumor) and ypN0 had a 5-year survival rate of
64%, the rate was only 18% in those with a minor re-
sponse and ypN(+).
However, Holscher’s prognostic classification was
based on histological response in esophageal adenocar-
cinoma. Information regarding the prognostic impact of
histological response in esophageal squamous cell car-
cinoma (ESCC) is limited in the literature. In this study,
we aimed to evaluate the prognostic impact of histo-
logical factors in patients with ESCC after preoperative
chemoradiation and esophagectomy.
Methods
We retrospectively reviewed the records of 91 consecu-
tive ESCC patients who had undergone preoperative
chemoradiation followed by transthoracic esophagec-
tomy at the Taipei Veterans General Hospital between
January 2009 and December 2014. Since patients with
cervical ESCC would be treated with definitive chemora-
diation, only patients with intrathoracic ESCC were in-
cluded. Preoperative staging workup were previously
described [8]. In particular, endoscopic ultrasound (EUS)
was an optional procedure, but was required for con-
firmation of cT1 or cT2 lesions.
Preoperative chemoradiation included two courses of
chemotherapy that were administered with a 4-week
interval. The chemotherapy regimen included 80 mg/m2
of cisplatin administered intravenously on day 1 followed
by continuous intravenous infusion of 600 mg/m2 5-
fluorouracil (5-FU) and 90 mg/m2 leucovorin on days 1
through 4 concurrently with 45–50.4 Gy of external-
beam radiation with the dose per fraction of 1.8 to 2 Gy
for primary tumors and mediastinal lymph node regions.
The clinical target volume was defined as the gross tar-
get tumor volume delineated on CT scans and other
diagnostic images along with 3–5-cm cephalic and at
least 5-cm caudal margins. A chest CT scan was rou-
tinely performed after chemoradiation to determine the
resectability.
Surgical resections were performed using the
McKeown tri-incisional esophagectomy method. The
surgical approaches used were minimally invasive esoph-
agectomy (MIE, right-sided video-assisted thoracoscopic
surgery [VATS] plus laparoscopic surgery) and hybrid
esophagectomy (right-sided VATS plus laparotomy). The
details of surgical procedures were previously described
[8]. Pathological examination that was conducted ac-
cording to the 7th edition AJCC TNM staging system
[9]. Tumor response was graded using the CAP (College
of American Pathologist) Cancer Protocol for Esopha-
geal Carcinoma [10]. Tumor regression grade (TRG) 0
(complete response) indicated no residual cancer cells.
TRG 1 (moderate response) was defined as minimal
residual cancer; TRG 2 (minimal response), as partial re-
gression of the tumor; and TRG 3 (poor response) indi-
cated that there was no definite response identified. The
presence of lymphovascular invasion (LVI), perineural
invasion (PNI), and extracapsular invasion (ECI) was re-
corded. The presence of tumor cells at proximal or distal
cut end, a circumferential margin of less than 1 mm, or
M1 stage indicated incomplete resection.
Patients who were living after the operation were
followed-up at our outpatient department. OS was de-
fined as the time from the date of diagnosis until
death or last known follow-up. Disease-free survival
(DFS) was defined as the interval between surgical re-
section and the first detection of recurrence, death,
or the last evaluation for recurrence. Patients who
died due to surgery-related complications and those
with M1 disease detected at the time of the surgery
were excluded from the DFS analysis.
The Institutional Review Board of the Taipei-Veterans
General Hospital approved this study and granted a wai-
ver for the informed consent process.
Statistical analysis
The Pearson Chi-square test was used to compare cat-
egorical variables. The Student t-test and ANOVA were
used for comparison of continuous variables. Survival
curves, plotted by the Kaplan–Meier method, were com-
pared by the log-rank test. The Cox regression model
was utilized in prognostic factor analysis. All calculations
were performed using Statistical Product and Service
Solutions (version 17, SPSS Inc., Chicago, IL) and a two-
sided p-values <0.05 was considered significant.
Results
Patient characteristics
Table 1 shows the detailed clinical and pathological
characteristics of the patients with ESCC as well as their
prognostic relevance. The mean age of the patients was
55.4 +/− 9.1 years. Four patients with clinical stage T1
tumors, but associate with clinical positive nodal in-
volvement were given chemoradiation before esophagec-
tomy. Five patients with ypM1 stage were because of
incidentally identified metastasis (lung or liver) during
esophagectomy. A total of 4 patients (4.4%) died of
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Table 1 Patient demographics and the relevance to overall survival
Variables No. of patients 3-years survival rate (%) Median survival, month (95% CI) p value
Age (yrs) 0.144
> 55 47 53.6 42.0 (19.1–64.9)
< =55 44 39.5 26.0 (17.2–34.8)
Sex
Male 88 46.3 32.0 (21.9–42.1) 0.799
Female 3 66.7 -a
Location 0.136
Upper third 24 35.4 15.0 (0.0–36.6)
Middle third 45 44.2 27.0 (13.7–40.3)
Lower third 22 64.5 -a
Differentiation 0.096
Grade I 3 33.3 12.0 (10.4–13.6)
Grade II 42 44.1 27.0 (12.6–41.4)
Grade III 11 37.9 11.0 (8.1–13.9)
N/A 35 57.0 -a
Tumor size (cm) 0.665
< 2.5 51 39.8 27.0 (13.4–40.6)
> = 2.5 40 54.4 37.0 (17.3–56.7)
cT stage 0.918
T1 4 50.0 -
T2 17 51.5 37.0 (21.0–53.0)
T3 66 45.7 27.0 (12.1–41.9)
T4 4 50.0 -a
cN stage 0.778
N0 27 36.5 32.0 (22.3–41.7)
N1 24 54.8 37.0 (9.06–64.9)
N2 17 41.0 21.0 (8.6–33.4)
N3 13 27.2 24.0 (17.4–30.6)
ypT stage 0.908
T0 32 53.4 37.0 (14.6–59.4)
Tis/1 11 42.4 25.0 (6.3–43.7)
T2 18 54.0 37.0 (15.5–58.5)
T3 24 34.1 27.0 (14.0–40.0)
T4 6 44.4 14.0 (2.2–25.8)
ypN stage 0.032 †
N0 56 53.5 37.0 (21.3–52.7)
N1 20 50.4 37.0 (2.0–72.0)
N2 12 13.0 15.0 (12.0–18.0)
N3 3 33.0 24.0 (0.0–49.6)
ypM stage 0.019 †
M0 86 49.1 35.0 (23.8–46.2)
M1 5 0.0 13.0 (0.1–25.9)
ypStage 0.031 †
0 25 63.8 -a
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surgery-related complications. The mean follow-up time
for the entire cohort was 22.0 months (range: 3 to
67 months). The median OS was 32 months (95% confi-
dence interval [CI], 21.9–42.1 months), with 1-year and
3-year OS rates of 78.7 and 46.5%, respectively. The me-
dian DFS was 11 months (95% CI, 4.5–17.5 months),
with 1-year and 3-year DFS rates of 49.1 and 27.5%, re-
spectively. Survival according to the AJCC staging is
shown in Fig. 1a.
Prognostic value of histological factors
In the Cox regression model, we did not include M stage
into the analysis because it was one of the characteristics
of incomplete resection. The univariate survival analysis
is shown in Table 2. Factors adversely affecting OS in-
cluded LVI, PNI, ypN stage, ECI, and incomplete resec-
tion. Unfavorable prognostic factors for DFS included
LVI, ECI, incomplete resection, and TRG. Since some of
these factors were highly correlated (for example, TRG
was significantly correlated with LVI and PNI; and ypN
stage was correlated ECI), we did not perform multivari-
ate analysis, trying to avoid the problem of multicolli-
nearity in a multiple regression model. Of these factors,
TRG, LVI, and PNI were the primary tumor features,
ypN stage and ECI were the lymph node features, and
resection margins were the surgical features. Patients
Table 1 Patient demographics and the relevance to overall survival (Continued)
I 7 42.9 25.0 (0.0–58.4)
II 30 52.2 37.0 (20.5–53.5)
III 24 34.9 16.0 (7.5–24.5)
IV 5 0.0 13.0 (0.1–25.9)
TRG 0.454
0 29 57.9 37.0
1 32 48.2 25.0 (5.8–44.3)
2 15 17.6 27.0 (12.4–41.6)
3 15 45.0 26.0 (3.6–48.4)
LVI 0.024 †
No 70 55.0 37.0 (26.3–47.7)
Yes 21 23.4 14.0 (8.9–19.1)
PNI 0.014 †
No 76 55.2 37.0 (26.1–47.9)
Yes 15 15.6 13.0 (9.4–16.6)
ECI 0.002 †
No 77 50.5 37.0 (23.9–50.1)
Yes 14 23.9 11.0 (7.9–14.1)
Total resected lymph node number 0.134
< 18 44 55.8 37.0 (21.4–52.6)
> =18 47 38.2 23.0 (10.6–35.4)
Incomplete resection 0.033 †
No 63 55.0 37.0 (26.1–47.9)
Yes 28 26.0 21.0 (9.5–32.5)
Surgical approach 0.950
MIE 62 47.9 35.0 (22.0–48.0)
Hybrid 29 30.7 27.0 (15.0–39.0)
Adjuvant therapy 0.434
No 67 47.4 32.0 (18.9–45.1)
Yes 24 42.4 35.0 (19.2–50.8)
CI confidence interval, TRG tumor regression grade, LVI lymphovascular invasion, PNI perineural invasion, ECI extracapsular invasion, MIE minimally invasive
esophagectomy and reconstruction; a:median survival not reached; †: p < 0.05
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with any of TRG2/3, LVI(+) or PNI(+) were character-
ized as having poor primary tumor factors, whereas pa-
tients with either ypN(+) or ECI (+) were regarded as
having poor lymph node factors. Patients with incom-
plete resection were considered as ha ving poor surgical
factors. The classification was based on the number of
poor histological factors and had a range from 0 to 3
(Table 3). Using Cox regression model, we demonstrated
that these factors have additional effect; which means,
patients with 1, 2, and 3 poor factors had HR of 1.576,
1.728, and 3.130 compared to those without any poor
factor in the overall survival analysis (p = 0.048). Patients
with 1, 2, and 3 poor factors had HR of 1.062, 2.030, and
2.958 compared to those without any poor factor in the
disease-free survival analysis (p = 0.027). We then classi-
fied patients with 0 poor histological factors as low risk,
those with 1 or 2 factors as medium risk, and patients
with 3 factors as high risk. In all, there were 40, 38, and
13 patients in the low-, medium-, and high-risk groups,
respectively. The 3-year OS was 60.1, 41.0, and 24.6% in
the low-, medium-, and high-risk groups, respectively.
The median survival (95% CI) was 46.0 (25.7–66.3), 26.0
(8.4–43.6), and 14.0 (10.6–17.4) months in the low-,
medium-, and high-risk groups, respectively (p = 0.013,
Fig. 1b). The 3-year DFS was 38.1, 27.0, and 0.0% in
low-, medium-, and high-risk groups, respectively. The
median DFS survival (95% CI) was 19.0 (8.0–30.0), 10.0
(0.8–19.2), and 5.0 (2.1–7.9) months in the low-,
medium-, and high-risk groups, respectively (p = 0.017,
Fig. 1c).
Impact of adjuvant therapy on patients with predicted
poor outcomes
We further evaluated the survival impact of adjuvant
therapy in ESCC patients predicted to have worse out-
comes after trimodality therapy. Of all the patients in
the medium- or high-risk groups, 23 received adjuvant
therapy whereas 28 received observation only. Although
there seemed to be a trend towards better OS in patients
receiving adjuvant therapy, no statistical significance was
reached; the 1- and 3-year OS rates were 95.5 and 39.5%
in patients receiving adjuvant treatment and 54.8 and
32.7% in those receiving observation only (Fig. 2a, p =
0.052). No significant difference was found between the
two groups in terms of DFS. The 1- and 3-year DFS
rates were 37.4 and 23.4% in patients receiving adjuvant
treatment and 51.4 and 17.1% in those receiving obser-
vation only (Fig. 2b, p = 0.824). On the basis of our ob-
servations, it is suggested that adjuvant therapy did not
Fig. 1 Survival curves according to AJCC staging system (a) and our
own classification (b overall survival; c disease free survival). The
curves were plotted with Kaplan-Meier method and compared with
log-rank test
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have a significant effect on survival in patients with pre-
dicted poor outcome.
Discussion
The current 7th AJCC staging system was based on the
retrospective analysis of patients who underwent surgery
without induction treatment or adjuvant therapy [9].
The prognostic value of such pathologic staging for pa-
tients who received preoperative treatment is question-
able [11–13]. For example, Kim et al. have shown that
the staging system was not very predictive of survival in
patients after preoperative treatment. In particular, there
was less distinctiveness among stage subgroups. Supple-
mentation of the AJCC TNM staging system with patho-
logic response for a better prediction of patients’
outcomes has been proposed for a long time [14]. In-
deed, the pathological response of the tumor is a critical
determinant of survival in patients receiving neoadjuvant
treatment. Although chemoradiation responders have
superior survival, the 5-year survival is only 18–27% in
poor responders [3–6, 15, 16]. Some authors reported
that non-responders to chemoradiation received no
benefit and had even worse survival compared to pa-
tients treated with primary esophagectomy [4–6]. By
combining classifications of primary tumor regression
and lymph node status, Hölscher et al. have established
a 3-grade classification with a good performance in
prognostic discrimination [7]. However, Holscher`s
prognostic classification was based on histological re-
sponse in esophageal adenocarcinoma. Information re-
garding the prognostic classification of histological
response in ESCC is limited in the literature. In the
present study, we demonstrated the prognostic value of
histological parameters including TRG, LVI, PNI, ypN
stage, ECI, as well as incomplete resection, in ESCC. In
addition to the well-known poor prognostic factors, such
as TRG, ypN, and incomplete resection, our prognostic
classification also includes LVI, PNI, as well as ECI.
Schoppmann et al. have reported that both the 5-year
OS (14% vs. 60%, p < 0.001) and the 5-year DFS (14% vs.
49%, p < 0.001) were significantly reduced in patients
with positive LVI [17]. Chen et al. have also reported
that ESCC patients with PNI-negative tumors had a 1.7-
fold increase in the 5-year recurrence-free survival over
the 5-year DFS for with patients with PNI-positive tu-
mors [18]. As for ECI, D’Annoville reported that the pro-
portion of ECI detected in N1, N2, and N3 patients was
28% (21 of 73 patients), 51% (21 of 41 patients), and
70% (17 of 24 patients), respectively. The presence of
ECI seems to have negative additive impact on DFS, re-
gardless of the pN stage [19]. ECI detected after pre-
operative chemoradiation and esophagectomy have been
reported to be associated with a very dismal prognosis.
In D’Journo’s study, the 5-year DFS rates were 46% in
N0 patients, 36% in N+ with intracapsular invasion pa-
tients, and 11%, in N+ with ECI patients [20].
As the information provided by these histological fac-
tors can identify high-risk patients, the requirement of
more aggressive treatment for the patients with pre-
dicted poor outcomes has to be addressed; however, the
effect of adjuvant therapy in these patients is doubtful.
Only a few studies have evaluated the effect of adjuvant
therapy in patients who underwent trimodality treat-
ment; this is partially because postoperative chemother-
apy or chemoradiation is poorly tolerated in esophageal
cancer patients. For example, 46% of patients in Stile’s
Table 2 Prognostic factors for overall survival (OS) and disease free survival (DFS)
OS DFS
HR (95% CI) p value HR (95% CI) p value
TRG (2/3 vs. 0/1) 1.455 (0.801–2.645) 0.218 1.834 (1.035–3.248) 0.038*
LVI (yes vs. no) 2.009 (1.076–3.752) 0.029* 1.975 (1.040–3.752) 0.038*
PNI (yes vs. no) 2.226 (1.144–4.331) 0.019* 1.481 (0.693–3.164) 0.311
ypN stage (+ vs. −) 2.041 (1.123–3.708) 0.019* 1.628 (0.926–2.861) 0.090
ECI (yes vs. no) 2.804 (1.404–5.599) 0.003* 2.836 (1.401–5.740) 0.003*
Incomplete resection (yes vs. no) 1.897 (1.033–3.482) 0.039* 2.254 (1.248–4.071) 0.007*
N = 91 and 82 for OS and DFS analysis, respectively
HR hazard ratio, CI confidence interval, TRG tumor regression grade, LVI lymphovascular invasion, PNI perineural invasion, ECI extracapsular invasion; *: p < 0.05 by
Univariate Cox regression analysis
Table 3 Category of each ominous factors (primary tumor, lymph node and surgical) in our classification and the parameters in
each category
Category Tumor factor Lymph node factor Surgical factor
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study received adjuvant chemotherapy, and most of the
(89%) received only one cycle [21]. In the current study,
24 patients (26.4%) received adjuvant therapy: 11 of
them received adjuvant chemotherapy and 13 of them
received adjuvant chemoradiation. Of all patients, 18
(75%) completed the treatment. Out of 6 cases of incom-
plete treatment, 5 were due to disease progression, and
therefore, palliative chemotherapy was administered to
the patients instead. The sixth patient had pneumonia
with septic shock during the second course of
Fig. 2 Overall survival (a) and disease free survival (b) of medium/high risk patients with (green line) or without (blue line) adjuvant therapy. The
curves were plotted with Kaplan-Meier method and compared with log-rank test
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chemotherapy. High completion rates of adjuvant ther-
apy in this study may be related to the use of minimally
invasive surgical techniques that resulted in earlier re-
covery from surgical trauma and faster return to baseline
physical function, which, in turn, improved the delivery
of adjuvant therapy. However, in our series, there was no
significant difference in OS or DFS between patients
with or without adjuvant therapy, which was compatible
with the results from the literature. In the study by
Meredith et al., which included 301 patients with
esophageal adenocarcinoma (86.7%) and 46 patients with
ESCC (13.3%), the 5-year OS and DFS were 43 and 43%,
respectively, in patients who were treated with adjuvant
therapy and 46 and 48%, respectively, in those who were
not [6]. In their study, 34 of 262 patients (13.0%) re-
ceived adjuvant therapy after preoperative treatment and
esophagectomy. They found that adjuvant therapy had
no impact on survival outcomes in patients who re-
ceived trimodality treatment. As echoed in Meredith’s
study, adjuvant therapy was not a predictor of survival
in another study by Stiles et al. [21].
Our study has some limitations. First, EUS was not
performed in every patient. Some patients came to us
with intolerable dysphagia and near total endoscopic
obstruction, which made EUS infeasible. In such
cases, CT scan or bronchoscopy determined the cT3
and cT4 lesions. Second, data on tumor differenti-
ation, which was determined by pretreatment diagnos-
tic biopsy, was lacking for a large portion of patients.
Some patients were referred to us after being diag-
nosed elsewhere, and we did not have an access to
the biopsy specimens. Third, the small number of pa-
tients in this study limits the ability of the new classi-
fication to predict survival with significant difference
between groups. Furthermore, most patients in this
cohort were men, which, in agreement with the re-
sults from our nation-wide database, confirms that
ESCC is the male-predominant disease in Taiwan
[22]. Whether our prognostic classification can be applied
to female esophageal cancer patients remains to be eluci-
dated. Finally, although the present study is one of the few
studies examining the effect of adjuvant therapy in pa-
tients who received trimodality treatment for esophageal
cancer and is probably the first one discussing this topic
exclusively in terms of squamous cell carcinoma histology,
the sample size was small, and the assignment of patients
to adjuvant therapy or observation groups was not ran-
domized and subject to substantial bias. In general, the
main indications for adjuvant therapy include positive
lymph nodes, close margins, incomplete resection, and
the absence of postoperative complications. We believe
that further large-scale study is needed to validate our
findings and determine the role of adjuvant therapy in
high-risk patients.
Conclusions
Histological factors including primary tumor factor
(TRG, LVI, and PNI), lymph node factor (ypN stage and
ECI), and surgical factor (incomplete resection) has a
significant value in predicting survival in patients after
trimodality treatments. In the future, it will be essential
to establish a surveillance protocol to determine the role
of adjuvant therapy in high-risk patients.
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